Since October, a number of pharmaceutical companies have been fined for selling inferior drugs

【Pharmaceutical Network Industry News】With the development of China's pharmaceutical industry, the country's attention to drug safety is constantly increasing, and the supervision and inspection of pharmaceutical enterprises are also continuously increasing
.
Recently, many places have successively released a series of sampling results, many of which have been fined for illegal production and sale of inferior drugs, and many companies have been fined more than
100,000 yuan.
On October 10, the Yunnan Provincial Food and Drug Administration released two administrative punishment information disclosure data
.
According to the announcement, Longling County Shenlong Oxygen Plant was previously investigated for providing drugs to others for unlicensed production of drugs, and the Food and Drug Administration gave it a "warning" and fined it 5,000 yuan; Yunnan City Tou Xinyi Pharmaceutical Co.
, Ltd.
was found to have sold counterfeit medicine madder, and the circumstances were relatively minor and finally only counterfeit drugs and illegal gains
were confiscated.
On October 8, the Hubei Provincial Food and Drug Administration issued an administrative punishment information disclosure form
.
Hubei Yihao Pharmaceutical Co.
, Ltd.
failed to comply with the "Good Management Practice for Drug Operation" and sold substandard drug Jumbo Pills, and the NMPA imposed fines and confiscated illegal gains in accordance with Article 28 of the Administrative Punishment Law, Article 117.
1 and Article 126 of the Drug Administration Law, and Article 75 of the Implementation Regulations of the Drug Administration Law, and the amount of the fine was not disclosed
。 On October 8 and 10, the Sichuan Provincial Food and Drug Administration announced an administrative penalty information, Sichuan Xinkang Traditional Chinese Medicine Pieces Co.
, Ltd.
and Sichuan Fengchun Pharmaceutical Co.
, Ltd.
were both investigated for the production and sale of inferior drugs, which involved madder charcoal (batch number: 201001) and Xuanmai ganju granules (batch number: 210910).

The NMPA imposed a threefold fine in accordance with the new Drug Control Law, and in the end, Sichuan Xinkang Traditional Chinese Medicine Pieces Co.
, Ltd.
forfeited a total of 334,053.
50 yuan, and Sichuan Fengchun Pharmaceutical Co.
, Ltd.
fined and confiscated a total of 495,600.
77 yuan
.
Recently, the Anhui Food and Drug Administration also issued an administrative penalty notice, in which Anhui Zehua Guo Yao Pieces Co.
, Ltd.
was fined 110,000 yuan for producing and selling inferior drug vinegar myrrh; Anhui Yuankang Traditional Chinese Medicine Pieces Co.
, Ltd.
was fined 400,000 yuan
for illegally renting out production licenses.
In fact, since the beginning of this year, pharmaceutical companies have been fined for producing and selling inferior drugs
.
From the perspective of punishment, there are not a few
fines of more than 100,000 yuan for the production and sale of counterfeit drugs.
Behind the huge fines imposed by many pharmaceutical suppliers for "eating" inferior drugs, the supervision of the pharmaceutical industry is becoming stricter and the cost of violating the law is greatly increasing
.
The industry generally believes that with the implementation and advancement of the new version of the Drug Administration Law and the tightening of supervision of the pharmaceutical industry, the illegal sales of inferior drugs by these pharmaceutical companies have been exposed one after another, which will continue to sound the alarm for
the industry.
For pharmaceutical companies, quality is the life of the enterprise, and only by standardizing production, operation and sales behavior, establishing and improving the quality management system of pharmaceutical business, and continuously improving product quality can we accelerate the development of enterprises and better cope with the increasingly strict supervision
of the industry.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.